环丙沙星与伊伐卡托涂层鼻窦支架抗铜绿假单胞菌生物膜的体外评价
本研究开发并优化了一种负载环丙沙星和伊伐卡托的可生物降解鼻窦支架(CISS),体外评估其药物涂层稳定性、释放动力学及抗铜绿假单胞菌生物膜效果。结果显示CISS涂层均匀,药物持续释放21天,放置3天后显著降低预形成生物膜的生物量(RODUs 0.31 vs 裸支架0.78 vs 对照1.0,p=0.001,n=3)。
要点
- CISS涂层均匀,药物持续释放21天且无初始突释。
- CISS放置3天可显著降低预形成的1天铜绿假单胞菌生物膜量。
- RODUs:CISS 0.31±0.01 vs 裸支架0.78±0.12 vs 对照1.0±0.00,p=0.001,n=3。
核心结论
- CISS保持均匀涂层并持续释放药物,显著减少铜绿假单胞菌生物膜形成。
- 计划在临床前模型中进一步评估CISS的疗效。
研究设计与样本
- 体外研究:将环丙沙星/伊伐卡托纳米粒与丙烯酸酯及甲基丙烯酸铵共聚物包覆于可生物降解聚左旋乳酸支架上制成CISS。
- 体外评估包括:zeta电位评估纳米粒药物稳定性及扫描电镜评估涂层稳定性;测定药物释放动力学;计算590 nm光密度下相对光密度单位(RODUs)评估抗生物膜形成。
主要发现
- zeta电位和扫描电镜确认支架上存在药物且涂层均匀。
- 药物持续释放21天,无初始突释。
- 将CISS放置3天于预形成的1天铜绿假单胞菌生物膜上,观察到抗生物膜形成。
- CISS显著降低生物膜量:RODUs(590 nm光密度)CISS 0.31±0.01 vs 裸支架0.78±0.12 vs 对照1.0±0.00,p=0.001,n=3。
关键数值与推荐
- CISS显著降低生物膜量:RODUs(590 nm光密度)CISS 0.31±0.01 vs 裸支架0.78±0.12 vs 对照1.0±0.00,p=0.001,n=3。
- 药物持续释放21天,无初始突释。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We recently developed a novel ciprofloxacin-coated sinus stent capable of releasing antibiotics over a sustained period of time. Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has synergistic bactericidal activity with ciprofloxacin and also enhances sinus mucociliary clearance. The objective of this study was to optimize and evaluate the efficacy of a ciprofloxacin- and ivacaftor-releasing biodegradable sinus stent (CISS) in vitro. METHODS: A CISS was created by coating ciprofloxacin/ivacaftor-embedded nanoparticles with an acrylate and ammonium methacrylate copolymer onto a biodegradable poly-L-lactic acid stent. In-vitro evaluation of the CISS included: (1) assessment of drug stability in nanoparticles by zeta potential, and drug-coating stability within the CISS using scanning electron microscopy (SEM); (2) determination of ciprofloxacin- and ivacaftor-release kinetics; and (3) assessment of anti-Pseudomonas aeruginosa biofilm formation by calculating relative optical density units (RODUs) compared with control stents at 590-nm optical density. RESULTS: The presence of drugs and a uniform coating on the stent were confirmed by zeta potential and SEM. Sustained drug release was observed through 21 days without an initial burst release. Anti-biofilm formation was observed after placing the CISS for 3 days onto a preformed 1-day P aeruginosa biofilm. The CISS significantly reduced biofilm mass compared with bare stents and controls (RODUs at 590-nm optical density; CISS, 0.31 ± 0.01; bare stent, 0.78 ± 0.12; control, 1.0 ± 0.00; p = 0.001; n = 3). CONCLUSION: The CISS maintains a uniform coating and sustained delivery of drugs providing a marked reduction in P aeruginosa biofilm formation. Further studies evaluating the efficacy of CISS in a preclinical model are planned.
引用
- Cho DY, Lim DJ, Mackey C, et al. In-vitro evaluation of a ciprofloxacin- and ivacaftor-coated sinus stent against Pseudomonas aeruginosa biofilms. Int Forum Allergy Rhinol. 2019. PMID: 30702211. doi:10.1002/alr.22285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。